RogerKStrairMD

Hematologic Oncology

chief of Hematologic Malignancies/Hematopoietic Stem Cell Transplantation at Rutgers Cancer Institute of New Jersey, Professor of medicine at Robert Wood Johnson Medical School.

Join to view full profile

Dr. Strair is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Strair's full profile

Already have an account?

Office
2 Cooper Plz
Camden, NJ 08103
Phone+1 855-632-2667

Fax+1 732-790-0107

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1984 - 1988
Brigham and Women's HospitalResidency, Internal Medicine, 1981 - 1984
Albert Einstein College of MedicineClass of 1981

Certifications & Licensure

NJ State Medical License 1994 - 2025
CT State Medical License 1989 - 1994
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2011-2014
Inside Jersey Magazine Top Doctors Castle Connolly, 2009-2014
Top Doctors: New York Metro Area Castle Connolly, 2007-2014
Inside Jersey Top Doctors for Cancer Castle Connolly, 2012, 2014
New York Magazine: Top Doctors Castle Connolly, 2009-2010, 2014
America's Top Doctors for Cancer Castle Connolly, 2010-2013
NJ.com Top Doctors Castle Connolly, 2009
Join now to see all

Clinical Trials

12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder Start of enrollment: 1998 Dec 01
Terminated
Phase 1
Xcellerated T CellsTM for Non-Hodgkin's Lymphoma (NHL) Patients Start of enrollment: 2004 Mar 01
Unknown status
Phase 2
Gene Expression During Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Choline Magnesium Trisalicylate Start of enrollment: 2003 Mar 01
Terminated
Phase 1
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor Start of enrollment: 2001 May 01
Completed
Phase 1
LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma Start of enrollment: 2005 Feb 01
Terminated
Not Applicable
Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease Start of enrollment: 2005 Jan 01
Terminated
Phase 1
Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2004 Aug 01
Terminated
Phase 2
Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2009 Feb 01
Terminated
Phase 2
Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome Start of enrollment: 2010 Mar 01
Terminated
Not Applicable
Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation Start of enrollment: 2009 Oct 01
Terminated
Phase 1
Phase II Study of TPA Plus Dexamethasone & CMT in Hematologic Malignancies Start of enrollment: 2011 Mar 01
Terminated
Phase 2
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies Start of enrollment: 2014 Jan 01
Withdrawn
Phase 2
AML Therapy With Irradiated Allogeneic Cells Start of enrollment: 2014 Feb 01
Terminated
Not Applicable
Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia Start of enrollment: 2009 Jan 01
Completed
Phase 2
Lactobacillus Rhamnosus GG in Reducing Incidence of Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant Start of enrollment: 2013 Feb 18
Completed
Not Applicable
Romidepsin in Treating Patients With Steroid-Refractory Graft-versus-Host Disease Start of enrollment: 2014 Nov 01
Terminated
Not Applicable
Join now to see all

Publications & Presentations

PubMed

242 citations
Results of the phase i trial of RG7112, a small-molecule MDM2 antagonist in leukemia
Michael Andreeff, Kevin R. Kelly, Karen W.L. Yee, Sarit Assouline, Roger Strair
Clinical Cancer Research. 2016-02-15
18 citations
Adenovirus-Mediated Cytotoxicity of Chronic Lymphocytic Leukemia Cells
Daniel J. Medina, Wendy Sheay, Lauri Goodell, Pamela Kidd, Eileen White
Blood. 1999-11-15
39 citations
Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide.
Annie Im, Armin Rashidi, Tao Wang, Michael T. Hemmer, Margaret L. MacMillan
Biology of Blood and Marrow Transplantation. 2019-03-01

Press Mentions

Breast Cancer Awareness MonthOctober 7th, 2022
Small Mutations Identified Through Deep DNA Sequencing for AML and MDSDecember 9th, 2019
Physicians at Rutgers Cancer Institute of New Jersey Named as ‘Jersey Choice Top Doctors’October 31st, 2017
Join now to see all

Grant Support

Phase I Trial Of 12 0 Tetradecanoylphorbol 13 AcetateNational Cancer Institute2000–2001
Detection Of Viral Transaction In Primary CellsNational Cancer Institute1993
Detection Of Viral Transactivators In Primary CellsNational Cancer Institute1991–1993
Isolation Of A Human E1a-Like FactorNational Cancer Institute1989–1993
Isolation Of A Human E1a-Like FactorNational Cancer Institute1989